Lofexidine
NERVOUS SYSTEM
Also known as: (+/-)-Lofexidine, lofexadine, lofexidine HCl, lofexidine hydrochloride
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Lofexidine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 7 molecular targets, including Adra2b|Adra2c|Adra2a, ADRA2A and Nisch. Recorded indications include Opioid withdrawal.
- Approval status: ofp (first approved 2018 by the FDA).
- Molecular targets: Adra2b|Adra2c|Adra2a, ADRA2A, Nisch and ADRA2B (7 listed in DrugCentral).
- Indications: Opioid withdrawal.
- ATC code: N07BC04 (Drugs used in opioid dependence).
- Molecular formula: C11H12Cl2N2O; molecular weight 259.13 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Opioid withdrawal
Mechanism & targets
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Adrenergic receptor alpha-2 | Adra2b|Adra2c|Adra2a | unknown | IC50 8.60 |
| Alpha-2A adrenergic receptor | ADRA2A | agonist | Ki 8.36 |
| Nischarin | Nisch | unknown | Ki 8.25 |
| Alpha-2B adrenergic receptor | ADRA2B | unknown | Ki 7.17 |
| Alpha-2C adrenergic receptor | ADRA2C | unknown | Ki 7.16 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 6.90 |
| Adrenergic receptor alpha-1 | Adra1b|Adra1d|Adra1a | unknown | IC50 6.18 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-05-16 | FDA | — | US WORLDMEDS LLC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N07BC04 | NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › DRUGS USED IN ADDICTIVE DISORDERS › Drugs used in opioid dependence |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- FDA label: CYP2D6 · Actionable PGx
Chemical structure
| Molecular formula | C11H12Cl2N2O |
|---|---|
| Molecular weight | 259.13 g/mol |
| CAS number | 31036-80-3 |
| InChIKey | KSMAGQUYOIHWFS-UHFFFAOYSA-N |
| PubChem CID | 30668 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Lofexidine used for?
DrugCentral lists the following indications for Lofexidine: Opioid withdrawal.
How does Lofexidine work?
Its molecular targets in DrugCentral include Adra2b|Adra2c|Adra2a, ADRA2A (agonist), Nisch and ADRA2B.
When was Lofexidine first approved?
Lofexidine was first approved by the FDA in 2018.
What is the chemical formula of Lofexidine?
Lofexidine has the molecular formula C11H12Cl2N2O and a molecular weight of 259.13 g/mol.
Browse: all drugs starting with L · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1593 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL17860 — compound record and bioactivity
- PubChem CID 30668 — chemical identifiers
- DrugBank DB04948 — drug record
- FDA UNII UI82K0T627 — substance identity
- DailyMed: FDA labels for Lofexidine — current prescribing information (label search)
- UniProt P08913 (ADRA2A) — target protein
- UniProt P18089 (ADRA2B) — target protein
- UniProt P18825 (ADRA2C) — target protein
- UniProt P08908 (HTR1A) — target protein
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.